BACKGROUND: Fibroblast growth factors and their receptors regulate key cellular functions, such as proliferation, differentiation and survival. Herein, we studied the prevalence and prognostic role of fibroblast growth factor receptor 2 (FGFR2) amplification in patients with advanced gastric cancer (AGC) who received systemic chemotherapy. PATIENTS AND METHODS: The gene copy number of FGFR2 was investigated in 80 patients with AGC who received systemic chemotherapy. FGFR2 gene status was assessed by dual-color fluorescence in-situ hybridization. RESULTS: Among 80 patients, FGFR2 amplification was observed in seven cases (11.5%). Patients with FGFR2 amplification had significantly shorter overall survival (OS) than did those without FGFR2 amplification (9.1 vs. 16.5 months; p=0.037). In multivariate analysis, disease status and number of metastatic sites were associated with worse OS (p=0.015 and p=0.009, respectively). FGFR2 amplification tended to be correlated with a poorer outcome (p=0.080). CONCLUSION: FGFR2 amplification tended to result in a shorter survival period compared to cases without amplification. Copyright
BACKGROUND: Fibroblast growth factors and their receptors regulate key cellular functions, such as proliferation, differentiation and survival. Herein, we studied the prevalence and prognostic role of fibroblast growth factor receptor 2 (FGFR2) amplification in patients with advanced gastric cancer (AGC) who received systemic chemotherapy. PATIENTS AND METHODS: The gene copy number of FGFR2 was investigated in 80 patients with AGC who received systemic chemotherapy. FGFR2 gene status was assessed by dual-color fluorescence in-situ hybridization. RESULTS: Among 80 patients, FGFR2 amplification was observed in seven cases (11.5%). Patients with FGFR2 amplification had significantly shorter overall survival (OS) than did those without FGFR2 amplification (9.1 vs. 16.5 months; p=0.037). In multivariate analysis, disease status and number of metastatic sites were associated with worse OS (p=0.015 and p=0.009, respectively). FGFR2 amplification tended to be correlated with a poorer outcome (p=0.080). CONCLUSION:FGFR2 amplification tended to result in a shorter survival period compared to cases without amplification. Copyright
Authors: Jamal H Carter; Catherine E Cottrell; Samantha N McNulty; Katinka A Vigh-Conrad; Stephen Lamp; Jonathan W Heusel; Eric J Duncavage Journal: Cold Spring Harb Mol Case Stud Date: 2017-11-21
Authors: Cheol Keun Park; Ji Soo Park; Hyo Song Kim; Sun Young Rha; Woo Jin Hyung; Jae-Ho Cheong; Sung Hoon Noh; Sang Kil Lee; Yong Chan Lee; Yong-Min Huh; Hyunki Kim Journal: Oncotarget Date: 2016-11-01
Authors: Jinglin Zhang; Yuhang Zhou; Tingting Huang; Feng Wu; Yi Pan; Yujuan Dong; Yan Wang; Aden K Y Chan; Liping Liu; Johnny S H Kwan; Alvin H K Cheung; Chi Chun Wong; Angela K F Lo; Alfred S L Cheng; Jun Yu; Kwok Wai Lo; Wei Kang; Ka Fai To Journal: Oncogene Date: 2018-08-06 Impact factor: 9.867
Authors: Jinglin Zhang; Chi Chun Wong; Kam Tong Leung; Feng Wu; Yuhang Zhou; Joanna H M Tong; Ronald C K Chan; Hui Li; Yifei Wang; Huan Yan; Liping Liu; William K K Wu; Michael W Y Chan; Alfred S L Cheng; Jun Yu; Nathalie Wong; Kwok Wai Lo; Ka Fai To; Wei Kang Journal: Oncogene Date: 2020-09-15 Impact factor: 9.867